initi buy pt
pioneer develop ipsc-bas off-the-shelf therapi
treatment cancer still earli stage develop
investor excit around therapeut platform stem broad
applic data begin emerg think investor
assign greater probabl platform becom derisk
earli stage platform compani
ipsc product clinic multipl data readout
think derisk platform initi studi
product dose escal studi refractori patient show good
safeti show strong activ immun respons tumor earli
sign efficaci patient think stock go safeti
signal aris stock could trade cash
see stock go slowli data read throughout next
month
evalu two studi one combin
concept patient respond
low mhc class express nk cell recogn kill cancer
cell regul mhc class look safeti immun
activ preliminari efficaci higher dose
think underappreci asset high affin
bind antibodi combin antibodi work
adcc proof concept come patient respond better
adcc therapeut mutat bind antibodi
high affin initi studi combin rituxan
look see respons patient refractori
rituxan advantag vs competitor need
intact immun system efficaci success program could
car-nk abil disrupt cellular therapi
cheaper make dose repeatedli like need solid
tumor like better safeti could begin see data
valuat risk
pt deriv use probability-adjust dcf give
protmun use
discount rate believ appropri smid cap biotech risk
tr target
invest thesis- invest platform compani poc data multipl
faith
nk cell basic could disrupt cellular therapi
ipsc-bas cell approach specif focu nk cell view fate platform
address sever challeng associ autolog cell therapi
state cell therapi
har power ipsc cell essenti convert cell type
fate special sauc involv take ipsc cell thu gener use clonal select
creat master ipsc cell line bank basi therapi
last year t-cell therapi flavor view nk cell address
challeng associ immunotherapi autolog car-t cell checkpoint
nativ nk cell recogn kill cancer cell
clinic evid use nk cell biolog nk cell base therapi target cancer deliv
anti-tumor effect
still nascent stage view data date support innov develop nk
cell therapeut cancer highlight presenc multipl player nk space
multipl modal includ ipsc base nk cell donor deriv placenta deriv cell nk cell
fate valuat base mainli ipsc platform includ ipsc base nk-cell therapi
preliminari data key catalyst
stock view
 expect data readout
ipsc base nk cell therapi deriv master ipsc cell line potenti synerg
checkpoint inhibitor expand opportun preliminari data studi evalu
combo like
page
think underappreci street
engin nk cell product clinic key highlight therapeut
engin cell facilit adcc data monotherapi aml rituxan
combo lymphoma like boost investor confid program
could disrupt cellular therapi
view investor excit fate car-nk potenti disrupt
autologous/allogen t-cell landscap fate ind recent clear see posit
read-through poc data car-nk trial
highlight key featur differenti fate platform drug
featur view fate engin under-appreci featur fate
featur fate drug given multipl dose dont reli patient intact
featur view ahead competit develop ipsc base cell
therapi cancer player still nascent stage could potenti first
market advantag
featur establish in-hous cgmp manufactur facil dedic ipsc-
page
key risk safeti one nk line toxic trial go hold could see
downsid lack efficaci /clinic trial risk financ risk
page
bull/bear srth casebul casebear casefair valuepric target valu valu po peak adjust salesprotmun po peak adjust salesprotmun fail contribut combin solid tumor po peak adjust combin solid tumor po peak adjust salesplatform safeti issu zero monotherapi aml po peak adjust monotherapi aml po peak adjust saleswithout faith platform expect stock could trade combin dlbcl po peak adjust combin dlbcl po peak adjust combin follicular lymphoma po peak adjust combin follicular lymphoma po peak adjust salespipelin valu peak adjust royalti partnershipspipelin valu peak adjust royalti partnership inc
invest thesis- invest platform compani poc data
multipl drug
up-front conclus pioneer develop ipsc-bas off-the-shelf therapi
treatment cancer still earli stage develop investor excit around
therapeut platform stem broad applic eas manufactur data
begin emerg program think investor assign greater probabl success
earli stage platform compani broad applic
faith
har power ipsc cell essenti convert cell type
compani initi focu nk cell oppos t-cell focu cell
therapi date
compani develop entir process manufactur ipsc cell in-hous ip
protect compani recent establish in-hous gmp facil expect manufactur
materi trial also streamlin manufactur process
earli proof-of-concept nk cell came collabor jeffrey miller work show
nk cell therapi high risk aml patient led orr
cell therapi past year focus autolog t-cell recent
allogen donor deriv collabor leader field engin ipsc
base cell therapi help prevent reject off-the-shelf nk cell host immun system
increas potenc persist make amen combo
importantli drug candid engin either increas adcc
combo monoclon antibodi engin base natur occur
mutat patient show increas surviv engin target antigen
express cancer cell poc approv car-t cell
last month time-fram compani abl get three ind involv
ipsc base cell accept fda
compani ipsc base therapeut clinic major investor interest
car-nk cell potenti compet effect autolog car-t
cell efficaci safeti provid off-the-shelf potenti cheaper option
still earli also develop ipsc base t-cell therapi could prove
disrupt car-t space autolog well allogen work
page
think greatli underappreci opportun next gener
version drug could combin antibodi work activ immun
respons via adcc potenti increas efficaci
ipsc nk cell line design increas efficaci drug work adcc cell
bind antibodi combin like rituxan exampl increas immun respons
could lead greater efficaci way work nk cell receptor
bind antibodi receptor bind fc portion antibodi essenti bring
immun system tumor proof concept work see detail page
drug develop increas adcc target receptor shown earli
efficaci howev drug antibodi rock analog bispecif
engin high affin bind receptor nk cell issu
method howev cancer patient often intact immun system nk cell
believ like see even greater respons potenti work peopl key
risk safeti year get lot data safeti profil earli efficaci data
program
page
per test trials/fat research proof nk cell alon taken peopl inject
cancer patient elicit respons
report go depth gener patient treat unmodifi
allogen nk cell major aml one studi patient relaps refractori aml
patient respons therapi well toler gvhd remark
nk cell short half-liv versu immun cell like t-cell design nk cell
line much longer half-liv even greater potenc
also abil platform disrupt cellular therapi
autolog allogen cellular therapi expens make even allogen
approach concern graft versu host host versu graft make simpl cell
line much cheaper put target receptor ipsc cell surfac alreadi
clinic advantag think solid tumor think repeat
dose requir allogen approach may expens lastli think side
effect much less approach other report outlin advantag ipsc
cellular therapi discuss biolog
begin see data nk ipsc line nk ipsc data
earli provid first glimps safeti potenti earli efficaci start year
get continu data unusu compani mani catalyst year
page
great thing mani pipelin product investor get data
continu larg pipelin roll clinic progress clinic trial date
ipsc call ink drug four ind clear multipl studi
begin read year
figur summari data readout drug clinic
strh research compani report
anoth possibl upsid compani could deal partner help develop
would reduc need financ frequent continu develop therapi
believ could possibl
figur summari model pipelin
compani report strh research
pt deriv use probabl adjust dcf probabl use figur
use discount rate believ appropri risk associ smid cap
page
drugindicationnear-term catalystcurr statusdescript ink solid tumor monotherapi combo patient either non-respons progress therapydata earli dose-escal cohort dose-escal on-going estim enrol actual studi start date master cell bank deriv nk cell engin combo ink cancer monoclon antibodi rituxan herceptin erbitux approv data earli dose-escal cohort dose-escal on-going estim enrol estim studi start date octob ipsc master cell bank deriv nk cell engin express optim non-cleav increas ink dlbcl diffus larg b-cell lymphoma initi clinic investig monotherapi combin monoclon antibodi treatment ofb-celllymphoma clear fda master cell bank deriv off-the-shelf nk cell incorpor engin optim anti-tumor ink fl follicular lymphoma initi clinic investig monotherapi combin monoclon antibodi clear fda master cell bank deriv off-the-shelf nk cell incorpor engin optim anti-tumor activ indicationlaunch year penetrationannu pricingunadjust salesadjust salesprob successprotmunemud combomrcc/adv rituxan combor/r rituxan combor/r valueroyalit potenti collabor inc
figur dcf
key risk safeti one nk line toxic trial go hold could see
downsid lack efficacy/clin trial risk financ risk
page
figur million free projectionsgaap ebit stock base depreci work capit capit free present valu net net incom return valu growth rate valu valu termin outstand valu per per valu per therapeut inc
nk cell basic could disrupt cellular therapi
ipsc-bas cell approach specif focu nk cell view
fate platform address sever challeng associ
state cell therapi
first gener cell therapi approv treatment cancer kymriah
novartiss nv nr car-t therapi target pediatr r/r r/r dlbcl
yescarta gilead hold karnauska car-t therapi target r/r dlbcl drug
shown efficaci late stage patient option left sever challeng
associ adopt drug includ safeti profil
includ neuro-tox requir hospit stay monitor potenti therapi
address crs/nt add cost therapi cumbersom manufactur process
depend health patient t-cell could take week manufactur could
potenti result heterogen product high cost manufactur process
contribut price drug complex logist restrict treatment larg academ
center limit singl dose relaps lead shorter durat benefit
figur process involv patient-deriv car-t cell immunotherapi
compani cellecti cll nr allogen nr focus allogen
therapi therapi deriv donor t-cell made avail cheaper off-
the-shelf develop therapi bog manufactur issu safeti
concern longer earli trial given earli stage platform
har power ipsc cell essenti convert cell type
fate platform base induc pluripot stem cell stem cell cell earli stage
develop self-repl convert cell type well-known
page
embryon stem cell ipsc technolog use engin adult donor cell fibroblast
stem cell ipsc self-renew convert cell type
figur gener human ipsc
fate special sauc involv take ipsc cell thu gener use clonal select
creat master ipsc cell line bank basi therapi
figur fate use proprietari process creat master ipsc cell line
page
bank cell start point compani establish pipelin product
initi focu nk cell compani establish collabor multipl expert field
jeffrey miller univers minnesota michel sadelain mskcc develop protocol
transform bank ipsc cell desir lineag
two autolog cell therapi alreadi approv yescarta kymriah note
signific challeng make cell therapi safer easili avail note key differ
autolog allogen ipsc cell base fate platform could potenti provid
advantag ipsc base cell therapi
page
figur compar autolog allogen ipsc base cell therapi
strh research compani report
page
autolog cell therapiesallogen cell therapiesipsc base cell therapiesst develop mani drug clinic yescarta kymriah approvedin clinic developmentin clinic developmentcel typet-cellst-cellsnk cells/t-cellssourc start materialcanc patientshealthi donorsorigin cell healthi young donor later engin ipscsqual start materiallow qualiti low quantiti depen health patienthigh consist qualiti vs autologoushigh qualiti sourc select qualiti expect higher consist vs autologousmanufactur challengesdifficult scale-up high qualiti control requirementswell-character donor cell line variabl occur differ donor cell line high qualiti control requir ensur isol engin cellswell-character master cell line ipsc consist replenish main risk residu undifferenti ipsc final productcogshighlow vs autologouslow vs autolog allogeneicimmun relat safeti concerns/gvhd risklow risk immun reject sinc patient cell use start material/no risk gvhdhigher risk immun reject need either lymphodeplet patient engin cell prevent immun reject gvhdrisk immun reject compar allogen t-cell nk cell unlik caus gvhd t-cell caus gvhd ipsc base cell therapi easier engin compar allogen cellsshelf-lif need administ immeidatelyshelf-lif must abl extend enabl storag productipsc expect surviv freeze/thaw process better adult cell differenti cell especi nk cell could better shelf-lif inc
last year t-cell therapi flavor view nk
cell address challeng associ immunotherapi
autolog car-t cell checkpoint inhibitor
data avail t-cell therapi approv multipl on-going clinic trial t-cell
therapi space believ greater investor confid t-cell therapi fate ipsc
base t-cell therapi develop preclin stage collabor lead car-t expert
michel sadelain mskcc compani initi focu ipsc base nk cell
nk cell natur killer cell part innat immun system innat immun consist
compon includ physic chemic barrier phagocyt cell neutrophil
macrophag dendrit cell natur killer cell blood protein includ member
complement system mediat inflamm provid first line defens
fact nk cell thought first line defens cancer main effector
cell innat immun system play import role target sick cell whether
viral infect cell tumor cell t-cell hand part adapt immun respons
recent focu cell therapi focus har t-cell treatment cancer fate
nk cell base strategi target cancer base literatur suggest nk cell present
altern approach potenti synergist t-cell highlight key featur nk cell
page
view support strategy- shorter respons time effector function independ
patient antigen nk cell need mhc recogn foreign cell instead recogn stress
signal cell common across wide varieti tumor regul inhibitori
receptor nk cell prevent nk cell target cytotox toward healthi cell nk cell
activ adapt immun system
strh research compani report
nativ nk cell recogn kill cancer cell
page
t-cellsnk cellsimmun system componentspecif immun adapt immun acquir immunitynon-specif immun nativ immun genet immunityspecificityrecogn specif antigen specif cell particl hla depend specif particular targetrecogn varieti differ group foreign cell particl abl target multipl targetstarget expressiontarget typic express particular tumorstarget overexpress mani tumor typesspe reactionslow sever hour sever daysrapid immedi sever hoursmemoryyesnonegvhdgvhd seriou issu allogeniec t-cell therapiesoff-the-shelf elicit gvhd tcr recogn host cellsbiolog cellst-cel biolog better understood vs nk cellsnk cell biolog less understood vs t-cell instanc cytokin activ nk cell cytokin releas inhibitori signal nk cell etc risk crs/neurotoxhighlowmutu effect naactiv adapt immun system activ t-cellssourc suntrust research http basicmedicalkey com/immune-system inc
clinic evid use nk cell biolog nk cell base therapi target cancer
deliv anti-tumor effect
figur summari clinic outcom nk cell trial
strh research compani report
still nascent stage view data date support innov develop
nk cell therapeut cancer highlight presenc multipl player nk
space multipl modal includ ipsc base nk cell donor deriv placenta
deriv cell nk cell engag
page
clinic outcom nk cell trialssourc nk cellspati tumor pr sdlymphoma cr praml complet remissionhematopoiet malign cr pr sdumbil cord blood nk cellshematopoiet malign consolidation/mainten month os os malign combin therapi cr praml consolidation/mainten set mrd-neg monthsrelapesd mm cr/near cr prautolog pb nk cellssolid tumor pr sdhematopoiet malign pr sdrelaps mm sdrelaps mm prmetastat melanoma kidney cancer responsesallogen pb nk cellssolid tumor pr sdlymphoma cr prhematopoiet malign consolidation/mainten month os os malign cr praml cr monthspediatr aml consolidation/mainten set durabl day yr aml consolidation/mainten set monthrefractori aml vs vs md cml crrefractori aml refractori md crpediatr refractori aml prior allo-sct cr underw allo-sct year relaps allo-sct cr underw allo-sct year aml cr month pr achiev cr year mo day mm cr/near cr pr sdlymphoma solid tumor sdsolid tumor sd sd monthspediatr refractori solid tumor pr sdovarian breast associ tumor lysi syndromeliv cancer cryosurgeri without nk cell vs monthsorr vs vs tumor colorect liver kidney cll prsourc suntrust research pleas ask us patient treat unmodifi allogeniec nk cell major aml respons r/r aml patient non-transpl set well-toler gvhd common infection/cytopenia inc
figur summari differ modal use channel nk cell biolog target cancer
strh research compani report
page
companyplatformsourc therapyproprietari attributesstag developmentnext catalystf ipsc base nk/t-cell therapi engineeredhealthi donor fibroblastipsc master cell bank deriv healthi donor fibroblast significantli ahead deriv seri ipsc ad engin function includ high affin multipl phase trial ongoingdata engin nk cell healthi donor deriv peripher bloodhighli special expans techniqu includ feeder cell co-stimulatori molecul genet modif persist tumor home bispecif target lead drug nk cell stage assetsind cell line cancer cell line deriv patient primari nk cell cord blood donor nk cell line engin either incorpor high affin bind receptor combin primayr cell treat nantsuperkin gener ciml nk cellslead product multipl studiesdata deriv nk cellscord bloodproprietari expans differenti platform close systemlead product multipl studiesnagamida celldonor deriv nk cellsperipher bloodnicotinamid nam technolog use increas number finction tumor target nk cell cell requir hla match lead nk base product studi heme malignanciesdata updat cell engag in-hous develop bispecif antibodi one part target tumor antigen target increas adcc redirect optim cell kill platform develop innat cell engag capabl reactiv innat immun cell includ nk cell macrophag kill cancer cell potenti registr trial on-going lead druginterim data pharmacheckpoint inhibit target nk t-cellsmonoclon antibodi develop nk cell inhibitori receptor nk inhibitori ligand found tumor on-going pivot trial initi earli updat allogen -t cell therapypati donor deriv use activ receptor express natur t-cell ligand express varieti trial on-going auto- allo- -t candidatesdata updat cell engagersin-hous develop tri-specif antibodiestrinket tri-specif nk cell engag therapi bind protein express cancer cell nk cellspre-ind stage assetsna inc
fate valuat base mainli ipsc platform includ ipsc
base nk-cell therapi preliminari data
key catalyst stock view
figur summari pipelin
figur summari model pipelin
compani report strh research
page
indicationlaunch year penetrationannu pricingunadjust salesadjust salesprob successprotmunemud combomrcc/adv combor/r rituxan combor/r rituxan combor/r valueroyalit potenti collabor inc
figur investor concern around fate ipsc platform strh take
strh research compani report
page
concernssuntrust takeipsc riski realli newwhil clinic data need feel comfort around platform accept ind past month earli data indic safeti concern increas invest ipsc deriv therapeut gilead bluerock therapeutics/bay evotec add confid platform program suffici differenti strong ip compani develop protocol in-hous repeat reproduc manag note platform back robust ip protect issu appli patent note us composit matter patent issued/licens exclus cover genom engin pluripot cell gener t-cell deriv pluripot stem cell drug manufactur differenti vs current avail autolog cellular therapi view ipsc easier reproduc less expens order magnitud also made avail off-the-shelf advantag ipsc cell renew sourc cell singl reprogram engin clone donor expand time lead ident ipsc cellscan ipsc deriv cell turn malign drug fulli differenti cell nk t-cell target diseas also tumor toxicolog studi done compani ind packag extens dose higher expect use peopl inc
figur detail summari pipelin data catalyst
strh research compani report
page
drugindicationnear-term catalystunadjust sale modelcurr statusdescript drugprotmuneallogen hematopoiet stem cell transplant blood data patient control trial trial initi patient enrol data expect program mud transplant reduc occur aml ovarian lungdata patient enrol data dose-escal on-going date total patient enrollednk cell haplo-ident donor program ex vivo inhibitor latter treatment lead activ persist adapt memori nk ink solid tumor monotherapi combo patient either non-respons progress therapydata earli dose-escal cohort dose-escal on-going estim enrol actual studi start date master cell bank deriv nk cell engin combo ink cancer monoclon antibodi rituxan herceptin erbitux approv data earli dose-escal cohort dose-escal on-going estim enrol estim studi start date octob ipsc master cell bank deriv nk cell engin express optim non-cleav increas ink dlbcl diffus larg b-cell lymphoma initi clinic investig monotherapi combin monoclon antibodi treatment ofb-celllymphoma clear fda master cell bank deriv off-the-shelf nk cell incorpor engin optim anti-tumor ink fl follicular lymphoma initi clinic investig monotherapi combin monoclon antibodi clear fda master cell bank deriv off-the-shelf nk cell incorpor engin optim anti-tumor ink multipl myelomapreclin trialnapreclin trialipsc master cell bank deriv off-the-shelf nk cell use combin monoclon antibodi therapi support daratumumab-medi hematolog malignanciespreclin trialnapreclin trialipsc master cell bank deriv off-the-shelf nk cell first-of-kind t-cell product candid engin featur includ antigen specif promot trac-regul express complet elimin tcr express mitig gvhd inc
 expect data readout late
ipsc base nk cell therapi deriv master ipsc cell line
potenti synerg checkpoint inhibitor expand
opportun preliminari data studi evalu combo
like
fatess first allogen ipsc-deriv product also first ipsc-deriv cell therapi
advanc clinic trial us
engin function enhanc way test monotherapi
combo provid proof concept ipsc candid
rf make longer act
figur fate first ipsc candid clinic data expect
question rational test unengin nk cell
yet see efficaci data remind investor fate donor deriv nk cell
program observ clinic activ aml ovarian cancer solid tumor
provid proof concept
page
figur summari efficaci aml voyag trial ovarian cancer apollo three
differ advanc solid tumor monotherapi dimens
anoth question around rational use nk combo particularli patient
progress treatment
failur occur patient low mhc class express like mutant make
patient recogn t-cell recogn nk cell kill
figur rational combo
page
run phase trial advanc solid tumor
earli safeti data patient encourag dlt patient progress next dose level
figur summari on-going trial solid tumor trial design
compani report strh research
expect get data on-going studi late
phase open-label dose escal studi on-going get data studi
throughout realli provid proof concept ipsc platform
safe potenti effect one trial evalu patient solid tumor fail
therapi trial still enrol go see data initi patient know
follow may patient treat one cycl cells/dos three
elig receiv second cycl cells/dos dlt sae august
learn patient treat second dose cells/dos well
toler patient elig receiv second dose second trial look
refractori patient evalu combin know patient
treat low dose wer dlt sae patient could go second dose
page
stagephas phase designopen-label dose-escalatingopen-label dose-escalatingtumor typesvari solid tumor checkpoint approvedvari solid tumor checkpoint approvedpati populationadvanc tumor fail approv therapiesadvanc tumor combo patient fail respond progress initi respons therapydos dose cycl dose escal dose cycl dose escal cells/dosedata updat may patient treat one cycl cells/dos elig receiv second cycl cells/dos dlt relat saesnadata updat aug patient treat dose cells/dos toler patient elig receiv patient treat cells/dos dlt relat sae patient elig receiv dose inc
figur summari know on-going studi
strh research compani report
given cell modifi way test
progressor view indic efficaci posit expect mainli safeti
think rational combo support preclin evid howev
expect cell effect patient loss occur
patient progress given compani select all-com may
abl see impact suggest preclin data unless patient select enrich
popul
view trial test safeti dose strategi like help evalu
impact ipsc base nk cell immun statu patient
highlight data earli small cohort patient
treat lower dose cell
given cell modifi way test pd-
progressor view indic efficaci posit
basic safe right dose go forward
stimul immun system way like shrink tumor
figur data readout data expect patient enrol
strh research compani report
page
drugtrial stagedesignpati populationdos scheduledata updat may updat aug open-label dose-escalatingadvanc tumor fail approv dose cycl dose escal patient treat one cycl cells/dos elig receiv second cycl cells/dos dlt relat patient treat dose cells/dos toler patient elig receiv open-label dose-escalatingadvanc tumor combo patient fail respond progress initi respons dose cycl dose escal patient treat cells/dos dlt relat sae patient elig receiv dosedrugnext data readoutdata expectedimmunolog activ data immunolog respons dose activ activ nk statu regulatori cytokin durabl dose efficaci immunolog activ data inc
think underappreci street
engin nk cell product clinic key highlight therapeut
engin cell facilit adcc data monotherapi
aml rituxan combo lymphoma like boost investor confid
program
view engin underappreci aspect fate engin cell
design fate base two concept natur occur receptor nk
cell involv nk cell mediat antibody-depend cellular cytotox increas adcc
correl improv outcom natur occur variant v/v
higher affin fc domain antibodi shown correl increas adcc
receptor express natur nk cell mediat antibody-depend cellular cytotox
mani fda-approv antibodi includ herceptin erbitux rituximab darzalex etc bind
monoclon antibodi initi releas perforins/granzym nk cell lead
figur antibodi depend cellular cytotox mediat nk cell
mani protein engin method test augment adcc natur
occur variant shown correl increas adcc
main strategi enhanc adcc function alter fc portion mab increas
bind affin activ fciiia chang fc domain glycosyl remov fc
domain fucosyl enhanc affin human antibodi natur killer nk cell-
express fcriiia glyco- protein-engin fc portion demonstr
highlight two approach believ provid clinic support idea modifi
fc domain increas adcc nr margetuximab antibodi
page
engin increas bind polymorph nr bispecif
antibodi increas bind nk cell macrophag increas nk cell activ
figur summari data margetuximab
strh research macrogen compani report
figur summari data immun cell engag
strh research affim compani report
page
portion engin increas affin allelephas trialsophia studi metastat breast cancer versu herceptin control armphas datamedian prolong versu control patient month allel patient month median os prolong versu control patient month allel patient monthsupfront conclus modifi monoclon antibodi increas affin appear correl improv innat cell engag bring nk cell macrophag bind tumor bind epitop optim bind epitop larg occupi circul antibodi phase trialtrial evalu preliminari efficaci monotherapi r/r lymphoma cutan presentationphas orr includ cr pr seen patientsphas combin keytruda r/r nhlphase datacombin well toler orr cr report patientsbispecif innat cell engag bridg nk cell macrophag bind tumor therapeut inc
fate design base natur occur variant v/v
higher affin fc domain antibodi
view fate strategi support data patient natur occur variant
see data margetixumab data trial
data support concept increas affin antibodi
posit impact efficaci
figur high affin variant nk cell lead increas bind improv
patient treat two differ antibodi
figur summari multipl studi indic increas adcc seen v/v polymorph
strh research compani report
page
indic treatment patientsfc gamma iiia mutant associ respons rate freedom progressionwegn wk clin oncol associ favor month mutat vs month without zhang clin oncol breast genotyp correl orr adcc analysi show genotyp greater herceptin mediat cytotoxicitymusolino clin oncol harbor v/v genotyp significantli higher erbitux mediat adcc correl found polymorph respons rate time progressionnegri fv pharmacogenom breast allele-restrict pcr benefit neoadjuv trastuzumab plu lapatinib bcmusolino pharmacogenom therapeut inc
figur engin high affin non-cleav expect increas
adcc combo monoclon antibodi
numer clinic studi fda-approv tumor-target antibodi includ rituximab
trastuzumab cetuximab demonstr patient homozyg high-affin
receptor improv clinic outcom
figur preclin data support use combin lymphoma data
cytokin prime donor nk cell support use nk cell therapi aml
page
figur summari on-going trial r/r aml r/r lymphoma trial design
strh research compani report
talk manag trial design highlight key learn
trial arm one monotherapi cell dose combo arm
fda would like compani find monotherapi combo instead
start lowest dose
expand patient popul enrich biolog like hla express level
expect enrol patient parallel could go anoth dose escal
cell
r/r aml trial use monotherapi support nk cell therapi data
patient well preclin data believ rational combin monoclon
antibodi strong lymphoma
enhanc work line expect could expand potenti market
across multipl indic use combin monoclon antibodi
approv treatment cancer
figur sale select monoclon antibodi approv oncolog
page
stagephas phase designopen-label dose-escalatingopen-label dose-escalatingpati populationmonotherapi r/r amlcombo rituxan r/r lymphomados dose cycl dose escal dose cycl dose escal cells/dos mabdata updat may updat aug patient treat dose cells/dos toler patient elig receiv patient treat cells/dos dlt relat sae patient elig receiv ww sale monoclon antibodi approv treatment cancer million inc
could disrupt cellular therapi
view investor excit fate car-nk potenti
see posit read-through poc data car-nk trial
fate engin nk cell therapi three activ anti-tumor modal includ
target product recent clear ind trial initi shortli
figur design fate car-nk therapi
drug uniformli engin three activ anti-tumor function compon high
affin non-cleav facilit increas adcc combin monoclon antibodi
express optim nk cell biolog receptor fusion
prolifer activ nk t-cell
compani clinic data view vitro data compar
primari cart cell indic compar efficaci cell kill lymphoma cell line vs
primari car-t cell enhanc respons combin antibodi
page
proof-of-concept come phase clinic trial use cord blood deriv car-nk cell data
r/r lymphoma patient show
patient r/r b-cell malign treat nk cell therapi deriv
cord blood see posit read-through fate enter clinic
figur proof concept
compani report strh research
page
drug/targetcord blood edriv car-engin nk cell engineeringnk cell deriv cord blood engin target b-cell co-stimulatori domian suicid switch enhanc prolifer activ nk cellspati inclus posit r/r patient receiv least line chemo target therapi persist diseas all/cll/nhl patient relaps diseas follow soc stem cell transplantphas trialtrial evalu safeti efficaci car-nk r/r b-cell malignanciesphas patient dlbcl cll fl phase datacombin well toler orr cr report patient inc
recent clear ind compani initi clinic trial r/r b-cell malign well
clinic protocol submit fda develop consult clinic
investig sever lead t-cell medic center
compani intend investig monotherapi combin rituxan
treatment r/r b-cell lymphoma advanc cll
in-lin on-going trial plan administ use multi-dos
page
highlight key featur differenti fate
platform drug
featur view fate engin under-
appreci featur fate platform
fate gener cell etc engin express non-
cleavabl high affin version increas adcc use conjunct monoclon
rational engin high affin come clinic data indic patient
natur occur variant high affin nk cell better respond herceptin
research suggest key differenti featur amongst compet nk cell base
nk cell bind antibody-co tumor cell via fc receptor initi releas perforin
granzym result tumor cell death
adcc contribut anti-tumor activ mani fda-approv antibodi provid expans
opportun target broad spectrum cancer
occur variant key differ two
affin fc domain antibodi patient homozyg
clinic data patient variant shown greater respons tumor target
antibodi rituximab trastuzumab cetuximab
fate ipsc therapi includ design express high affin variant
test current aml solid tumor patient combin mab
note compani engin product bind note
drug bispecif antibodies/dart none nk
cell base compani appear use strategi date
fate drug also engin express non-cleav version anoth
differenti factor circumv down-regul typic seen
context tme
cancer patient particularli context tme shown undergo
consider down-regul like impact endogen nk cell activ
fate non-cleav circumv issu
research indic none competitor engin way
page
featur fate drug given multipl dose dont reli
patient intact immun system
fate drug cellular therapi optim high anti-tumor activ
depend endogen immun cell popul given off-the-shelf natur
therapeut given multipl dose
nk cell engag develop compani depend endogen nk cell popul
anti-tumor effect fate nk cell engin differ function
combin combin mab target
provid cytokin independ persist nk cell shown anti-tumor activ
preclin model addit requir patient intact immun system
howev note possibl nk cell engag work conjunct fate nk
featur view ahead competit develop
ipsc base cell therapi cancer player still nascent
stage could potenti first market advantag
player date ipsc deriv cell therapi space bluerock bayer bayn-d nr
sana privat centuri privat gilead hold karnauska centuri
therapeut expect develop ipsc base cell therapi cancer t-cell player
compani ind ipsc deriv cell therapi accept fda alreadi
clinic earli poc data expect next month
note field also sever player develop donor deriv nk cell
view greater challeng around engin vs ipsc cell
talk manag learn nk cell like engin cryo-preserv
remind engin nk cell engin ipsc cell transform engin cell
nk cell master cell bank need also donor deriv nk cell dont recov
well post cryo-preserv post-thaw viabil take massiv hit concern
circumv fate platform
featur establish in-hous cgmp manufactur
facil dedic ipsc-deriv cell therapi
facil launch earlier octob in-lin timelin indic compani
view key mileston addit posit ipsc base cell therapi pioneer
page
compani in-hous manufactur capac talk manag learn follow
individu therapeut separ master cell bank master cell bank
get intermedi api continu manufactur process stage
cell cryo-preserv
in-hous facil expect build inventori intermedi api
cell expand final batch within day
continu much last day manufactur capac
limit last day singl ipsc thaw stagger last day everi
page
manag compens align well sharehold interest
overal compens plan appear line sharehold interest name execut offic
elig earn incent bonu base individu perform goal well corpor goal
relat product develop advanc clinic studi compens
execut structur around achiev corpor goal mileston year
base subject object perform goal determin board director
page
figur summari model assumpt
figur summari statu current drug probabl success assign
strh research compani report
 model peak unadjust sale mrcc advanc nsclc progressor
mutat assign probabl success peak adjust sale add
dcf
figur summari revenu build combin mrcc advanc nsclc
strh research compani report
page
indicationlaunch year penetrationannu pricingunadjust salesadjust salesprob successprotmunemud combomrcc/adv rituxan combor/r rituxan combor/r valueroyalit potenti collabor catalystunadjust sale modelcurr statusdescript drugprotmuneallogen hematopoiet stem cell transplant blood data patient control trial trial initi patient enrol data expect program mud transplant reduc occur aml ovarian lungdata patient enrol data dose-escal on-going date total patient enrollednk cell haplo-ident donor program ex vivo inhibitor latter treatment lead activ persist adapt memori nk ink solid tumor monotherapi combo patient either non-respons progress therapydata earli dose-escal cohort dose-escal on-going estim enrol actual studi start date master cell bank deriv nk cell engin combo ink cancer monoclon antibodi rituxan herceptin erbitux approv data earli dose-escal cohort dose-escal on-going estim enrol estim studi start date octob ipsc master cell bank deriv nk cell engin express optim non-cleav increas ink dlbcl diffus larg b-cell lymphoma initi clinic investig monotherapi combin monoclon antibodi treatment ofb-celllymphoma clear fda master cell bank deriv off-the-shelf nk cell incorpor engin optim anti-tumor ink fl follicular lymphoma initi clinic investig monotherapi combin monoclon antibodi clear fda master cell bank deriv off-the-shelf nk cell incorpor engin optim anti-tumor ink multipl myelomapreclin trialnapreclin trialipsc master cell bank deriv off-the-shelf nk cell use combin monoclon antibodi therapi support daratumumab-medi hematolog malignanciespreclin trialnapreclin trialipsc master cell bank deriv off-the-shelf nk cell first-of-kind t-cell product candid engin featur includ antigen specif promot trac-regul express complet elimin tcr express mitig combo revenu summari us eu row ww sale inc
model peak unadjust sale r/r aml assign probabl success
everi peak adjust sale add dcf
figur summari revenu r/r aml
strh research compani report
model peak unadjust sale r/r dlbcl r/r fl assign
probabl success peak adjust sale add dcf
figur summari revenu combin r/r dlbcl fl
strh research compani report
pt deriv use probabl adjust dcf probabl use figur
use discount rate believ appropri risk associ smid cap
page
r/r aml sale aml r/r aml patient treat revenu dlbcl line dlbcl line dlbcl line dlbcl r/r dlbcl revenu dlbcl dlbcl dlbcl r/r dlbcl revenu dlbcl dlbcl dlbcl r/r dlbcl revenu r/r follicular lymphoma sale r/r fl r/r fl revenu inc
strh research compani report
page
incom adjust dlbcl fl platform oper oper itemsloss extinguish incom expens provis rate net ep ep base extinguish net ep ep dilut s/o use inc
strh research compani report
page
balanc sheet figur asset equival market invest relat matur expens current current contract liabilitiesaccount portion cirm award portion defer portion defer liabil unvest equiti portion current award liabil net current term equiti liabil inc
figur statement flow
strh research compani report
page
statement figur flow from/ use oper activ net incom gaap non-oper item depreci base debt discount debt issuanc premium discount collabor contract interest mileston charg chang fair valu exchang common stock licens payment includ loss extinguish loss extinguish expens current payabl accru chang work cash provid by/ use oper flow from/ use invest activ proce sale properti properti short-term short-term cash provid by/ use invest flow from/ use financ activ issuanc common stock equiti incent plan net repurchas issuanc public offer common stock net issuanc privat placement issuanc common stock net issuanc privat placement issuanc prefer stock net issuanc sale common stock collabor cirm long-term long-term payment includ loss extinguish debt issuanc cash provid by/ use financ includ restrict includ restrict inc
figur dcf
key risk safeti one nk line toxic trial go hold could see downsid lack efficacy/clin trial
page
figur million free projectionsgaap ebit stock base depreci work capit capit free valu growth rate valu valu termin outstand valu per per valu per therapeut inc
mr wolchko presid chief execut offic respons compani financ administr
oper mr wolchko began career invest banker co serv six year firm new
york citi menlo park california offic member invest bank group assist emerg
growth compani health care technolog sector complet capital-rais transact prior join mr
wolchko serv chief offic bocada inc oversaw corpor service-rel oper previous led
corpor develop drugstor com respons sourc evalu execut financi busi develop
opportun mr wolchko hold biochem engin univers virginia biomed engin
univers vermont
dr shoemak chief scientif offic overse compani discoveri preclin develop effort
dr shoemak previous chief scientif offic icxbiosystem led discoveri develop molecular tool enrich
analyz rare cell popul applic advanc detect technolog use biodefens cancer prenat diagnost
previous dr shoemak cso technolog led research develop rapid ultrasensit detect assay
biodefens clinic point-of-car diagnost dr shoemak held variou posit increas respons
merck research laboratori includ director target discoveri senior director rosetta inpharmat research fellow
depart molecular neurosci main focu target identif biomark discoveri dr shoemak research
merck result multipl public top scientif journal includ natur scienc natur biotechnolog dr shoemak receiv
ph biochemistri stanford univers biochemistri univers california santa barbara
bahram bob valamehr chief develop offic overse compani earli develop activ includ
off-the-shelf cell therapi product candid deriv compani induc pluripot stem cell platform previous dr valamehr
vice presid cancer immunotherapi prior play key scientif role center cell control nih
nanomedicin develop center broad stem cell research center develop novel method control pluripot modul
stem cell fate includ hematopoiesi better understand cellular signal pathway associ cancer co-author
numer studi patent relat stem cell biolog oncolog materi scienc dr valamehr receiv ph
depart molecular medic pharmacolog ucla pepperdin univers depart
chemistri biochemistri ucla
page
overal compens plan appear line sharehold interest name execut offic elig earn incent bonu
base individu perform goal well corpor goal relat product develop advanc clinic studi
compens execut structur around achiev corpor goal mileston year base
subject object perform goal determin board director
page
inc oper biopharmaceut compani dedic develop
program cellular immunotherapi cancer immun disord firm programm cellular
therapeut treatment life threaten diseas hematolog malign genet disord
diseas result dysregul immun system product includ prohema
protmun adapt nk ipsc-deriv nk program cell therapi compani
found philip beachi sheng ding rudolf jaenisch randal moon michael rudnicki david
scadden leonard zon alexand rive scott wolchko john mendlein april
headquart san diego ca
rate buy ipsc product clinic multipl data readout think
derisk platform initi studi product dose escal studi
refractori patient show good safeti show strong activ immun respons
tumor earli sign efficaci patient think stock go safeti signal
aris stock could trade cash see stock go slowli data read
throughout next month look good safeti
sign immun system boost earli efficaci think platform broad applic
underappreci
valuat risk
pt deriv use probabl adjust dcf probabl use protmun
use discount rate believ appropri
risk associ smid cap biotech key risk safeti one
nk line toxic trial go hold could see downsid lack efficacy/clin trial risk
compani mention note
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
